Novo Nordisk has more than enough of its Wegovy weight-loss pills to support an aggressive product launch, CEO Mike Doustdar ...

Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs ...

Trump deals with Eli Lilly and Novo Nordisk increase access to obesity drugs, providing a safe, convenient way to slim down ...

A dramatic corporate governance battle reached its climax at Novo Nordisk on Friday when the company's majority shareholder forced a complete boardroom overh ...

Scholar Rock soared by 24.41 percent on Friday to close at $37.41 apiece as investor sentiment was boosted by the progress of ...

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...

Dow Jones Top Company Headlines at 1 PM ET: Walmart's Doug McMillon to Step Down as CEO After Over a Decade | JBS ... John Furner will become the retail giant's fifth CEO since founder Sam Walton.

Europe’s day saw major moves in trade, UK tax policy, a BBC apology to Trump, and big board changes at Novo Nordisk.